A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Brief description of study

If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect of two drugs Ipilimumab and Brentuximab Vedotin when given together. Purpose: The goal of the study is to determine the highest dose that is well tolerated, called the maximum tolerated dose (MTD), side effects that are severe, how often the tumors shrink, called the complete response (CR) rate and partial response rate (PR) and overall response rate (ORR), how long the tumors stay shrunk, called the duration of remission (DOR), how long the tumor takes to start growing again after treatment, called progression-free survival (PFS) and how long patients live, called overall survival (OS) of the combination of Brentuximab Vedotin and Ipilimumab in relapsed/refractory Hodgkin lymphoma patients.

Clinical Study Identifier: S14-00011
ClinicalTrials.gov Identifier: NCT01896999

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.